We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.01%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$880M
AUM Growth
-$133M
Cap. Flow
-$37.2M
Cap. Flow %
-4.23%
Top 10 Hldgs %
31.67%
Holding
96
New
7
Increased
26
Reduced
40
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$9.09M
2
BSX icon
Boston Scientific
BSX
+$8.75M
3
TMO icon
Thermo Fisher Scientific
TMO
+$7.35M
4
HUM icon
Humana
HUM
+$7.34M
5
RPRX icon
Royalty Pharma
RPRX
+$6.15M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$16.1M
2
CNC icon
Centene
CNC
+$15.7M
3
MCK icon
McKesson
MCK
+$10.2M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.43M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLK
76
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$2.13M 0.24%
140,000
– –
ARVN icon
77
Arvinas
ARVN
$588M
$2.1M 0.24%
+50,000
New +$2.51M
NKTR icon
78
Nektar Therapeutics
NKTR
$2.53B
$2.09M 0.24%
36,667
-4,259
-10% -$269K
PHAT icon
79
Phathom Pharmaceuticals
PHAT
$693M
$1.99M 0.23%
235,210
– –
PHR icon
80
Phreesia
PHR
$769M
$1.88M 0.21%
75,000
-42,000
-36% -$925K
IONS icon
81
Ionis Pharmaceuticals
IONS
$9.46B
$1.85M 0.21%
50,000
-21,000
-30% -$792K
GTHX
82
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.56M 0.18%
316,137
– –
STXS icon
83
Stereotaxis
STXS
$143M
$1.47M 0.17%
797,330
– –
RIGL icon
84
Rigel Pharmaceuticals
RIGL
$778M
$1.38M 0.16%
122,508
-5,269
-4% -$106K
RPID icon
85
Rapid Micro Biosystems
RPID
$85.2M
$1.29M 0.15%
300,000
– –
EPIX
86
DELISTED
ESSA Pharma
EPIX
$1.18M 0.13%
375,000
-35,923
-9% -$201K
ANNX icon
87
Annexon
ANNX
$883M
– –
-250,000
Closed -$683K
BIIB icon
88
Biogen
BIIB
$30.6B
– –
-15,000
Closed -$3.16M
CNC icon
89
Centene
CNC
$32.9B
– –
-187,000
Closed -$15.7M
GDRX icon
90
GoodRx Holdings
GDRX
$1.25B
– –
-235,000
Closed -$4.54M
MGNX icon
91
MacroGenics
MGNX
$259M
– –
-287,081
Closed -$2.53M
OLMA icon
92
Olema Pharmaceuticals
OLMA
$1.04B
– –
-500,000
Closed -$2.13M
PVLA
93
Palvella Therapeutics
PVLA
$2.19B
– –
-3,750
Closed -$909K
ACCD
94
DELISTED
Accolade Inc
ACCD
– –
-200,000
Closed -$3.51M
OSH
95
DELISTED
Oak Street Health, Inc.
OSH
– –
-150,000
Closed -$4.03M
BHVN
96
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-136,000
Closed -$16.1M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Rhenman & Partners Asset Management held 96 positions worth $880M, down 13% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $37.2M in Q2 2022, closing 10 positions and reducing 40 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Royalty Pharma worth $6.31M.

  • Rhenman & Partners Asset Management's largest Q2 2022 buy was Royalty Pharma: 150,000 shares worth $6.31M.
  • Rhenman & Partners Asset Management added most to Abbott in Q2 2022, an estimated $9.09M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2022 reduction was McKesson, cutting an estimated $10.2M.
  • Rhenman & Partners Asset Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $16.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $880M portfolio in Q2 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q2 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 13% quarter-over-quarter to $880M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.